Compare BioNano Genomics Inc (BNGO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Meta Platforms Inc — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Meta Platforms Inc trades at $579.49 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 112005.9× BioNano Genomics Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | META | |
|---|---|---|
Market Cap | $13.66M | $1.53T |
Sector | Health | Media |
52-Week High | $4.92 | $790.00 |
52-Week Low | $1.06 | $525.72 |
Enterprise Value | $16.26M | $1.55T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
META trades at $599.12, up 0.71% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations at $10.44 EPS versus $6.70 expected, though Q2 2026 missed estimates. Technical indicators show neutral signals with support at $594 and resistance at $608. The company maintains robust revenue growth, reaching $201B in 2025, while investing heavily in AI infrastructure including the recent Muse Spark launch.
Wall Street remains bullish with 79% buy ratings and $761.95 consensus target, representing 27% upside. Key opportunities include AI monetization potential and strong cash flow generation, while risks involve regulatory lawsuits and elevated capital expenditures. The stock presents a compelling growth story but faces execution risks in competitive AI landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
